Obesity is a chronic
inflammation with increased serum levels of
insulin,
insulin-like growth factor 1 (IGF1), and
interleukin-17 (IL-17). The objective of this study was to test a hypothesis that
insulin and IGF1 enhance IL-17-induced expression of inflammatory
chemokines/
cytokines through a
glycogen synthase kinase 3β (GSK3B)-dependent mechanism, which can be inhibited by
melatonin. We found that
insulin/IGF1 and
lithium chloride enhanced IL-17-induced expression of C-X-C motif
ligand 1 (Cxcl1) and C-C motif
ligand 20 (Ccl20) in the Gsk3b(+/+) , but not in Gsk3b(-/-) mouse embryonic fibroblast (MEF) cells.
IL-17 induced higher levels of Cxcl1 and Ccl20 in the Gsk3b(-/-) MEF cells, compared with the Gsk3b(+/+) MEF cells.
Insulin and IGF1 activated Akt to phosphorylate GSK3B at
serine 9, thus inhibiting GSK3B activity.
Melatonin inhibited Akt activation, thus decreasing P-GSK3B at
serine 9 (i.e., increasing GSK3B activity) and subsequently inhibiting expression of Cxcl1 and Ccl20 that was induced either by
IL-17 alone or by a combination of
insulin and
IL-17.
Melatonin's inhibitory effects were only observed in the Gsk3b(+/+) , but in not Gsk3b(-/-) MEF cells.
Melatonin also inhibited expression of Cxcl1, Ccl20, and
Il-6 that was induced by a combination of
insulin and
IL-17 in the mouse prostatic tissues. Further, nighttime human blood, which contained high physiologic levels of
melatonin, decreased expression of Cxcl1, Ccl20, and
Il-6 in the PC3 human
prostate cancer xenograft
tumors. Our data support our hypothesis and suggest that
melatonin may be used to dampen IL-17-mediated
inflammation that is enhanced by the increased levels of
insulin and IGF1 in
obesity.